This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of predominantly men with primary biliary cholangitis with cirrhosis, ursodeoxycholic acid response ...

Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is an autoimmune disorder characterized by intrahepatic cholestasis. While the precise etiology and pathogenesis ...

Primary biliary cirrhosis (PBC) is a chronic cholestatic disorder that potentially leads to end-stage liver disease. It has an autoimmune component: patients have high serum levels of ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual ...

WASHINGTON, DC — Measures of liver stiffness remained stable or improved in patients with primary biliary cholangitis (PBC) after 36 months of treatment with seladelpar (Livdelzi) based on new data ...

FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects ...

—A Danish cohort study found higher levels of the inflammation marker SCD163 were associated with lower quality of life in primary biliary cholangitis patients. Patients with primary biliary ...

The European Medicines Agency (EMA) has recommended that a conditional marketing authorization should be granted for Iqirvo (elafibranor; Ipsen Pharma) for treating primary biliary cholangitis (PBC).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% ...

More than half of patients saw a biochemical response by 1 year with the novel oral agent ...

Ursodeoxycholic acid (UDCA) is the only drug approved for treating primary biliary cirrhosis, but recent meta-analyses have cast doubt on its long-term benefits. Corpechot and colleagues have examined ...